###### Significance of this study

What is already known about this subject?
=========================================

-   The expression of dipeptidyl peptidase-4 (DPP4) has been shown to be dysregulated in obesity, type 2 diabetes mellitus (T2DM), non-alcoholic fatty liver disease and cardiovascular diseases. However, it is unclear if increased circulating plasma DPP4 levels are  associated with the development of obesity and diabetes.

-   Higher plasma DPP4 levels have been reported in obese as compared with non-obese individuals, but there are conflicting reports on circulating plasma DPP4 levels in subjects with T2DM of different ethnic groups.

What are the new findings?
==========================

-   This is the first study reporting elevated levels of circulating plasma DPP4 in young, non-obese Asian Indian patients with T2DM, on metformin therapy and diagnosed within 1 year from onset. Further, elevated circulating plasma DPP4 levels in patients with T2DM correlate with measures of anthropometry, skinfolds, intra-abdominal adipose tissue and hepatic fat.

-   We report fasting serum insulin, low-density lipoprotein cholesterol, triceps skinfolds, total intra-abdominal adipose tissue volume and presence of diabetes as significant determinants of circulating plasma DPP4 levels in non-obese Asian Indians with T2DM residing in North India.

How might these results change the focus of research or clinical practice?
==========================================================================

This study has significant implications for DPP4 inhibitors therapy in non-obese Asian Indians with T2DM.

Introduction {#s1}
============

Asian Indians have a body phenotype featured by excess body fat, higher truncal, subcutaneous and intra-abdominal adipose tissue, and lower muscle mass as compared with white Caucasians.[@R1] 'Non-obese' Asian Indians (as defined by body mass index (BMI) \< 25 kg/m^2^) also exhibit similar body composition features with biochemical features of insulin resistance. Further, associated with type 2 diabetes mellitus (T2DM) in 'non-obese' Asian Indians are excess liver span and increased pancreatic volume (surrogate markers for ectopic fat deposition in liver and pancreas, respectively), as reported previously by our group.[@R2] Despite these reports, the pathogenesis of T2DM in such 'non-obese' Asian Indians remains poorly understood.

Dipeptidyl peptidase- 4 (DPP4) is an exopeptidase glycoprotein of 110 kilodaltons released from differentiated adipocytes and ubiquitously expressed on the surface of a variety of cells and tissues such as pancreas, liver, spleen and adrenal glands.[@R3] DPP4 exerts both paracrine and endocrine effects and is involved in cell signaling and insulin action. It selectively cleaves N-terminal dipeptides from cytokines, growth factors, neuropeptides and incretin hormones.[@R4] The substrate for DPP4, namely glucagon-like peptide-1, is responsible for 60% of postprandial insulin secretion. It is inactivated by DPP4 within 20 minutes of release,[@R5] leading to decreased plasma insulin levels resulting in elevation of blood glucose levels.[@R6]

The expression of DPP4 has been shown to be dysregulated in obesity,[@R7] T2DM, non-alcoholic fatty liver disease (NAFLD)[@R8] and cardiovascular diseases.[@R9] Higher plasma DPP4 levels have been reported in obese as compared with lean Chinese men.[@R10] Further, circulating plasma DPP4 levels are increased in Danish patients with T2DM,[@R11] while decreased plasma DPP4 levels were reported in Irish Caucasian patients with T2DM.[@R12] In one of the few studies on correlations of DPP4 expression with abdominal adipose tissue compartments, circulating DPP4 levels was positively correlated with BMI, subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in German patients with wide ranges of BMI. Specifically, in lean subjects (mean BMI: 22±2 kg/m^2^) with impaired glucose tolerance, DPP4 expression was higher in VAT than SAT, and correlated positively with the amount of VAT, adipocyte size and adipose tissue inflammation. It has been opined that DPP4 may be a marker for visceral obesity, insulin resistance and the metabolic syndrome.[@R13] Preliminary data also show that circulating DPP4 levels correlated with advanced glycosylation end (AGE) products and that AGEs significantly increased plasma DPP4 release from tubular cells and increased DPP4 expression in Japanese patients, thus suggesting their potential importance in the development of complications of diabetes as well.[@R14]

DPP4 inhibitors have been used successfully in the treatment of T2DM globally.[@R15] In this context, research on DPP4 is particularly relevant for Asian Indians who have increasing prevalence of  diabetes, generalized obesity and excess abdominal adiposity. Importantly, adipose tissue compartments, posterior abdominal SAT[@R16] and deep abdominal SAT have been strongly linked to insulin resistance,[@R17] especially in Asian Indians.[@R18]

Previous investigators did not specifically study circulating plasma DPP4 levels in non-obese patients (defined by BMI) with T2DM. Importantly, the relationships of circulating plasma DPP4 with various adipose tissue subcompartments-abdominal SAT (anterior, posterior and deep subcutaneous abdominal adipose tissue) and total intra-abdominal adipose tissue, (intraperitoneal and retroperitoneal adipose tissue, pancreatic volume and liver fat, which may have relevance to insulin resistance, have not been previously defined.

In view of the above gaps in knowledge and pursuant to possible association of circulating plasma DPP4 to intra-abdominal obesity in non-obese Asian Indians with T2DM, we conducted the present research. We hypothesized that 'non-obese' Asian Indians with T2DM may have increased circulating plasma DPP4 levels as compared with non-obese, normoglycemic subjects and aimed to show that such increased levels would correlate with waist-to-hip ratio, skinfolds, abdominal SAT, intra-abdominal adipose tissue (IAAT) volume, liver span (as surrogate measure of NAFLD,) pancreatic volume (surrogate marker for pancreatic, lipids) and fasting serum insulin levels.

Methodology {#s2}
===========

Ethical approval was obtained from the institutional review board and the study was conducted according to the Declaration of Helsinki 2013.[@R19] The details of subject recruitment, inclusion and exclusion criteria and so on are mentioned in our previous study.[@R2]

Briefly, non-obese (BMI [\<]{.ul}25 kg/m^2^) patients with T2DM (cases: males n=83, females, n=10), diagnosed within one year from onset, and BMI-matched, normoglycaemic subjects (controls: males, n=24, females, n=16), aged between 18--40 years were recruited. In the first phase of the study, we recruited more of male T2DM subjects (n=83) as compared with females (n=10). This was because a higher number of male subjects fulfilled the recruitment criteria as compared to females.

None of the patients was on insulin therapy, sulfonylureas, DPP4 inhibitors, pioglitazone or any other antihyperglycemic treatment other than metformin. Those who were on metformin were continued on this drug and dose was modified as per clinical requirement. Peripheral skinfolds (biceps, triceps, thigh and calf skinfolds; sum of four skinfolds=total peripheral skinfolds) and truncal skinfolds (subscapular, suprailiac and abdominal skinfolds; sum of three skinfolds=total truncal skinfolds) were measured using a Lange skinfold calipers (Beta Technology, Santa Cruz, California, USA) as reported previously.[@R20] Further, 1.5 Tesla MRI imaging was carried out using T1-weighted axial scans at lumbar vertebra 2 and 3 to estimate the volumes of total abdominal adipose tissue and abdominal adipose tissue compartments, *viz* SAT (anterior, posterior, superficial and deep subcutaneous) and total IAAT (intraperitoneal and retroperitoneal) with liver span (surrogate measure of NAFLD) and pancreatic volume, using previously published protocols.[@R2] Pancreatic volume index was calculated as pancreatic volume (cm^3^)/body surface area (m^2^).[@R21]

Biochemical analysis {#s2a}
--------------------

Fasting and postprandial blood samples were analyzed for plasma glucose levels. Serum lipid profile, hepatic transaminases and glycosylated hemoglobin were analyzed in fasting blood samples by methods described previously.[@R2] Circulating plasma DPP4 and fasting serum insulin levels were measured by ELISA using commercial kits (USCN Life Science, Houston, Texas, USA). The intra-assay and inter-assay percentage coefficient variables for plasma DPP4 were 2.6 and 1.97, respectively. For serum insulin, the intra-assay and inter-assay percentage coefficient variables were 1.76 and 2.10, respectively.

Statistical analysis {#s2b}
--------------------

Data were analyzed using STATA 11.0 (College Station, TX, USA). Continuous variables were presented as Mean±SD using Student's t-test. As the data of cases and controls differed in age, the analysis of covariance (ANOCOVA) was used to adjust plasma DPP4 levels for age in cases and controls. The correlations of plasma DPP4 levels with measures of anthropometry, biochemical variables, and volumes of abdominal adipose tissue compartments, liver span and pancreatic volume were assessed using Pearson's correlation. Stepwise multiple regression analysis was performed to derive predictor variables for plasma DPP4 levels in both cases and controls. The *p* value less than 0.05 was considered statistically significant.

Results {#s3}
=======

In this study, significant differences were observed for biceps and triceps skinfolds in non-obese patients with T2DM (cases) as compared with controls after adjustment for age and gender ([table 1](#T1){ref-type="table"}). Importantly, significantly higher (p\<0.001) circulating plasma DPP4 levels were observed in cases as compared with controls ([table 2](#T2){ref-type="table"}). Significantly higher volumes of abdominal adipose tissue depots were observed in cases as compared with controls, after adjustment for age and gender as follows: total IAAT (49.7%; p*=*0.000), intraperitoneal adipose tissue (47.7%; p*=*0.000), retroperitoneal adipose tissue (70.7%; p*=*0.000) and liver span (10.8%; p=0.000). Specifically, no significant differences were observed between cases and controls for volumes of anterior subcutaneous, posterior subcutaneous, superficial and deep subcutaneous abdominal adipose tissue and total subcutaneous abdominal adipose tissue ([figure 1](#F1){ref-type="fig"}A--F, [table 3](#T3){ref-type="table"}). Further, NAFLD was observed in 48 cases (51.6%; 36 cases had grade 1 and 12 cases had grade 2 NAFLD) and two controls (5%; grade 1 NAFLD). Specifically, in patients with T2DM with NAFLD (n=48), the mean circulating plasma DPP4 level (52.6±27.8 ng/mL) was significantly higher (p\<0.05) as compared with patients with T2DM without NAFLD (n=43; mean circulating plasma DPP4 level; 47±28.3 ng/mL).

###### 

Anthropometric profile and skinfold measurements

                                            Unadjusted for age   Adjusted for age   p value                           
  ----------------------------------------- -------------------- ------------------ --------- ---------- ------------ ---------
  Body mass index (kg/m^2^)                 22.8±2.0             22.3±2.1           0.21      22.8±1.9   22.4±1.8     0.33
  Body surface area (cm^3^/m^2^)            1.72±0.1             1.67±0.2           0.09      1.7±0.09   1.6±0.18     0.97
  Waist circumference (cms)                 85.7±6.8             82.8±7.7           \<0.01    85.8±4.8   84.5±5.6     0.02
  Hip circumference (cms)                   89.5±4.6             90.8±7.3           0.23      89.3±4.8   91.3±5.0     0.06
  Waist-to-hip ratio                        0.95±0.0             0.90±0.0           \<0.001   0.95±0.0   0.90±0.0     \<0.001
  Mid-arm circumference (cms)               27.2±2.4             27.6±5.4           0.6       27.2±2.8   27.6±3.1     0.53
  Mid-thigh circumference (cms)             49.7±4.2             48.7±4.8           0.24      49.7±3.8   48.7±4.4     0.26
  Biceps skinfolds (mms)                    8.4±4.1              13.6±9.8           \<0.01    8.3±5.7    13.8±6.3     \<0.01
  Triceps skinfolds (mms)                   15.6±5.3             18.9±7.7           \<0.01    15.5±0.3   19.3±6.3     \<0.01
  Thigh skinfolds (mms)                     23.6±5.7             28.7±10.1          \<0.01    23.5±6.6   28.9±7.5     \<0.01
  Calf skinfolds (mms)                      12.4±5.2             21.8±8.4           \<0.01    12.4±5.7   21.9±6.3     \<0.01
  Subscapular skinfolds (mms)               22.2±5.8             21.8±8.5           0.79      21.9±6.7   22.3±6.9     0.8
  Suprailiac skinfolds (horizontal) (mms)   17.8±4.9             20.7±5.6           \<0.01    17.7±4.8   20.8±5.0     \<0.01
  Suprailiac skinfolds (vertical) (mms)     18.1±5.2             20.2±5.2           \<0.05    18.0±9.6   20.4±5.0     \<0.05
  Suprailiac skinfolds (average) (mms)      17.9±4.8             19.9±5.6           \<0.05    17.8±9.6   20.1±5.0     \<0.05
  Abdominal skinfolds (vertical) (mms)      23.9±5.3             24.1±7.8           0.87      23.8±5.7   24.6±8.1     0.61
  Abdominal skinfolds (horizontal) (mms)    24.8±5.4             24.1±7.6           0.60      24.8±5.7   24.6±8.1     0.91
  Abdominal skinfolds (average) (mms)       24.2±5.3             23.8±7.9           0.71      24.0±5.7   24.7±8.1     0.66
  Total peripheral skinfolds (mms)          60.1±17.3            78.0±35.2          \<0.01    59.8±24    78.7±23.9    \<0.001
  Total truncal skinfolds (mms)             106±21.8             102.0±29.6         0.32      106.7±24   101.9±25.2   0.32

Values are presented as Mean±SD; p\<0.05, statistically significant.

![Abdominal adipose tissue depots and pancreatic volume in a 29-year-old non-obese (BMI: 21.9 kg/m^2^) patient with type 2 diabetes, images obtained using MRI (1.5 Tesla) and quantified by ROI analysis using GE Advantage Workstation Volume Viewer softwares. (A) Superficial subcutaneous abdominal adipose tissue, (B) Deep subcutaneous abdominal adipose tissue, (C) Anterior subcutaneous abdominal adipose tissue, (D) Posterior subcutaneous abdominal adipose tissue, (E) Intraperitoneal adipose tissue and (F) Retroperitoneal adipose tissue.](bmjdrc-2017-000393f01){#F1}

###### 

Biochemical profile

  ---------------------------------------------------------------------------------------------------------------------------------------------
  Biochemical variables                              Unadjusted for age   p value      Adjusted for age   p value                   
  -------------------------------------------------- -------------------- ------------ ------------------ ------------ ------------ -----------
  Fasting blood glucose\                             147.8±51. 1          89.4±2.6     \<0.000            148.1±12.4   88.8±32      0.92
  (mg/dL)                                                                                                                           

  Postprandial blood glucose (mg/dL)                 222.6±82.9           89.36±13.7   \<0.01             222.9±70.5   79.8±12.6    \<0.01

  Fasting serum insulin\                             9.5±0.6              5.5±0.4      \<0.001            10.0±9.5     6.8±8.1      \<0.05
  (mIU/dL)                                                                                                                          

  Postprandial serum insulin (mIU/mL)                22.3±3.0             8.0±0.5      \<0.001            21.5±44.6    13.0±28.6    0.07 (NS)

  Glycosylated hemoglobin (%)                        9.00±2.5             5.2±0.37     \<0.01             9.0±2        5.1±2        \<0.001

  Total cholesterol (mg/dL)                          175.4±41.5           152.4±29.1   \<0.01             175.4±38.4   152.6±42.2   0.34

  Serum triglycerides (mg/dL)                        170.1±99.4           97.15±45.8   \<0.01             170.0±87.3   97.4±88.2    \<0.001

  High-density lipoprotein cholesterol (mg/dL)       40.7±8.9             42.4±8.3     0.31               40.8±8.6     42.4±8.1     \<0.05

  Low-density lipoprotein cholesterol (mg/dL)        110.3±31.2           96.81±25.3   \<0.05             110.2±29.7   98.0±29.6    \<0.001

  Very low-density lipoprotein cholesterol (mg/dL)   33.5±19.3            19.47±9.1    \<0.01             19.5±16.3    33.5±17.0    \<0.001

  Aspartate aminotransferase (U/L)                   57.81±21.7           45.60±18.1   \<0.01             57.9±20.1    47.1±21.4    0.17

  Alanine aminotransferase (U/L)                     27.89±12.8           23.68±9.1    \<0.05             27.8±11.5    24.6±11.9    \<0.001

  Serum dipeptidyl peptidase-4\                      52.0±3.0             20.1±2.3     \<0.001            50.2±9.6     23.5±6.3     \<0.001
  (ng/mL)                                                                                                                           
  ---------------------------------------------------------------------------------------------------------------------------------------------

Values are presented as Mean±SD; p\<0.05, statistically significant.

NS, not significant.

###### 

Abdominal fat depots, pancreatic volume and liver span measured by MRI (1.5 Tesla)

  Variables measured by MRI (1.5 Tesla)                    Unadjusted for age   Adjusted for age                                       
  -------------------------------------------------------- -------------------- ------------------ --------- ------------ ------------ ---------
  Anterior subcutaneous adipose tissue volume (cm^3^)      49.0±21.7            46.7±20.1          0.56      48.3±19.9    48.4±20.7    0.98
  Posterior subcutaneous adipose tissue volume (cm^3^)     55.8±20.6            57.0±19.4          0.75      55.2±19.9    58.0±20.1    0.41
  Superficial subcutaneous adipose tissue volume (cm^3^)   80.9±28.7            82.4±30.8          0.77      79.8±28.5    84.8±28.9    0.35
  Deep subcutaneous adipose tissue volume (cm^3^)          22.3±10.5            19.6±8.3           0.15      22.1±9.5     20.3±9.4     0.35
  Total subcutaneous adipose tissue volume (cm^3^)         103.3±35.3           102.1±38.0         0.86      101.9±35.1   105.1±35.2   0.64
  Retroperitoneal adipose tissue volume (cm^3^)            33.5±14.5            19.6±9.0           \<0.001   33.4±12.3    19.9±13.2    \<0.001
  Intraperitoneal adipose tissue volume (cm^3^)            69.3±29.5            48.0±22.0          \<0.001   62.2±27.5    44.4±27.7    \<0.001
  Total intra-abdominal adipose tissue volume (cm^3^)      102.8±39.8           68.5±30.5          \<0.001   69.1±37.0    49.3±37.8    \<0.001
  Liver span (mm)                                          165±16.5             149.0±19.1         \<0.001   165.1±17.1   149.0±17.6   \<0.001
  Pancreatic volume (cm^3^)                                67.4±24.9            53.2±20.8          \<0.01    67.1±23.7    53.9±23.9    \<0.01
  Pancreatic volume index (cm^3^)                          38.7±13.8            31.9±11.1          \<0.01    38.6±12.3    32.2±13.2    \<0.05

Values are presented as Mean±SD; p\<0.05, statistically significant.

Pearson's correlation analysis revealed significant positive correlation in cases for circulating plasma DPP4 with waist-to-hip ratio (online [supplementary figure 1](#SP1){ref-type="supplementary-material"}) and MRI quantified volumes of total IAAT (p\<0.001) ([figure 2](#F2){ref-type="fig"}) and liver span p \<0.05 (p\<0.001) (online [supplementary figure 2](#SP1){ref-type="supplementary-material"}). No significant correlation was observed between plasma DPP4 levels in T2DM patients with NAFLD. Further, no significant correlation was observed for pancreatic volume and pancreatic volume index, anterior subcutaneous, posterior subcutaneous, superficial deep SAT compartments and total abdominal fat. For biochemical variables, significant positive correlation was observed for circulating plasma DPP4 levels with fasting insulin in cases but not in controls (online [supplementary figure 3](#SP1){ref-type="supplementary-material"}). Importantly, circulating plasma DPP4 levels correlated negatively and significantly (p\<0.05) with high-density lipoprotein cholesterol (HDL-C) in cases but not in controls ([table 4](#T4){ref-type="table"} and online [supplementary figure 4](#SP1){ref-type="supplementary-material"}).
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![Showing significant positive correlation of circulating plasma DPP4 levels with total intra-abdominal adipose tissue volume in patients with T2DM (A) and lack of significant positive correlation of circulating plasma DPP4 with total intra-abdominal adipose tissue volume in non-obese, non-diabetic subjects (B). DDP4, plasma dipeptidyl peptidase-4; T2DM, type 2 diabetes mellitus. ](bmjdrc-2017-000393f02){#F2}

###### 

Correlation of  plasma DPP4 levels with waist-to-hip ratio, biochemical variables, total abdominal fat volume and Liver span in non-obese patients with T2DM  (Cases: n = 93) and non obese, non diabetic subjects (Controls: n = 40)

  -------------------------------------------------------------------------------------------------------------------------------------
                                                  Cases (n=93) \                      Controls (n=40) \                          
                                                  Pearson's correlation coefficient   Pearson's correlation coefficient          
  ----------------------------------------------- ----------------------------------- ----------------------------------- ------ ------
  Waist-to-hip ratio                              0.32                                0.04                                0.21   0.2

  Fasting serum insulin (ng/dL)                   0.31                                0.04                                0.09   0.39

  High density lipoprotein cholesterol (mmol/L)   −0.48                               0.02                                0.10   0.53

  Total abdominal fat volume (cm^3^)              0.24                                0.04                                0.10   0.75

  Total intra-abdominal fat volume (cm^3^)        0.19                                0.04                                0.04   0.78

  Liver span (mm)                                 0.24                                0.02                                0.10   0.98
  -------------------------------------------------------------------------------------------------------------------------------------

p\<0.05: statistically significant.

DDP4, plasma dipeptidyl peptidase-4; T2DM, type 2 diabetes mellitus.

On stepwise multiple linear regression analysis, variables such as fasting serum insulin, low-density lipoprotein cholesterol (LDL-C), triceps skinfolds, total IAAT volume and presence of T2DM were derived as significant determinants of circulating plasma DPP4 levels ([table 5](#T5){ref-type="table"}).

###### 

Stepwise multiple linear regression analysis for determinants of circulating plasma DPP4 levels

  Predictor variables                        Beta coefficient (95% CI)   p value
  ------------------------------------------ --------------------------- ---------
  Presence of diabetes                       7.1 (5.0 to 9.2)            0.001
  Fasting serum insulin                      0.23 (0.09 to 0.37)         0.04
  Triceps skinfold thickness                 0.25 (0.11 to 0.42)         0.02
  Total intra-abdominal fat volume (cm^3^)   0.40 (0.20 to 0.63)         0.001
  Low-density lipoprotein cholesterol        0.80 (0.14 to 0.92)         0.04

Adjusted r^2^ value: 0.57, p\<0.05: statistically significant.

DDP4, plasma dipeptidyl peptidase-4.

Discussion {#s4}
==========

Although circulating plasma DPP4 levels in T2DM have been researched, data in non-obese patients with T2DM are few. This is the first study showing elevated levels of circulating plasma DPP4 levels in young, non-obese Asian Indian patients with T2DM. Further, for the first time, correlations of circulating plasma DPP4 with anthropometric measures (including detailed skinfold thickness measurements), volumes of abdominal adipose tissue compartments, pancreatic volume and liver span have been carried out.

Specifically, circulating plasma DPP4 levels correlated significantly and positively with waist-to-hip ratio and IAAT volume in T2DM cases as compared with controls, even after adjustment for age and gender. Further, on stepwise multiple linear regression analysis, total intra-abdominal fat volume appeared a significant predictor (β coefficient: 0.40, p\<0.05) of circulating plasma DPP4 levels. Similarly, a recent CT-based study on elderly Japanese men with T2DM showed significant positive correlation between circulating DPP4 levels and intra-abdominal fat area, indicating that circulating DPP4 levels were significantly associated with intra-abdominal visceral fat in Japanese patients with T2DM.[@R22] Of note, as compared with white Caucasians, Asian Indians have higher magnitude of abdominal adiposity and larger adipocyte size[@R23] correlating with increased release of non-esterified free fatty acids.[@R24] It is reported that DPP4 levels correlate with adipocyte size and metabolic syndrome.[@R10] Whether increased intra-abdominal obesity and larger adipocytes in non-obese Asian Indians lead to concomitant increase in DPP4 levels needs to be researched.

We used liver span quantified by MRI as a measure of hepatic fat, and also graded fatty liver. Importantly, nearly 52% of patients with T2DM in this study had NAFLD and elevated DPP4 levels. DPP4 is highly expressed in the liver tissues and its activity has been correlated with hepatic steatosis and grading of NAFLD in North Americans[@R25] and Japanese subjects.[@R26] It is important to note that as compared with white Caucasians, hepatic triglyceride accumulation is significantly higher in Asian Indians and is associated with higher magnitude of insulin resistance.[@R27] In this context, our observations being reported for the first time in Asian Indians achieve clinical importance. Further studies in the context of plasma DPP4 levels and liver steatosis in Asian Indians are needed, using more specific measures of quantification of liver fat (eg, proton magnetic resonance spectroscopy).

In our study, patients were non-obese by definition of BMI, hence circulating plasma DPP4 levels may not be similarly increased as seen in studies done on obese patients. Second, patients with T2DM in our study were diagnosed within one year prior to recruitment and were already on lifestyle management and metformin therapy. Whether such management could alter levels of circulating plasma DPP4 levels and its relationship with abdominal adipose tissue compartments is not known. In this context, it is important to note that in Korean patients with T2DM on metformin therapy or dual combination therapy (metformin with thiazolidinedione), plasma DPP4 levels were lower as compared to patients with T2DM on other antihyperglycemic drugs. These observations were attributed to the suppressive effects of metformin and thiazolidinedione drugs on the *in vivo* release of the plasma isoforms of DPP4.[@R28]

Importantly, circulating plasma DPP4 levels have been reported to increase when HbA1c increases above 9.0%,[@R30] similar to patients in our study (HbA1c levels ranged between 9.0% and 11% (75--97 mmol/mol)). We also show significant positive correlations of fasting insulin with high circulating plasma DPP4 levels. It is unclear if high levels of circulating plasma DPP4 as seen in patients with marked hyperglycemia is a primary or secondary effect. It is possible that gene expression for plasma DPP4 is upregulated on exposure to elevated blood glucose levels.[@R31] In this context it is important to note that circulating plasma DPP4 levels are significantly upregulated by serum insulin levels[@R32] and tumor necrosis factor alpha[@R33], especially in patients with T2DM with non-alcoholic steatohepatitis.[@R34] Importantly, circulating plasma DPP4 levels in peripheral blood cells improved after better glucose control in drug-naive T2DM patients with T2DM, indicating the possible role of DPP4 in insulin signaling pathway.[@R33]

Of further importance, we observed significant negative correlation of circulating plasma DPP4 levels with HDL-C, despite lack of significant differences in mean values of HDL-C between the two groups. In a study on middle-aged Chinese individuals, HDL-C levels have been reported to correlate with plasma DPP4 levels only in subjects with diabetes and not in normoglycemic subjects.[@R26] Similar observations have been reported in another study on Chinese individuals.[@R10] Further in a study on non-obese, elderly Japanese subjects, HDL-C was shown to correlate independently with plasma DPP4 levels and showed significant dose--response relationship.[@R14] This interesting relationship should be investigated. Finally, independent correlations of LDL-C and circulating DPP4 levels need to be researched in view of high predisposition of Asian Indians for development of coronary heart disease.

The clinical significance of high circulating plasma DPP4 levels in 'non-obese' Asian Indians with diabetes is not clear, but some reported effects could be relevant. Specifically, subclinical inflammation may be increased by plasma DPP4 due to induction of obesity-induced inflammation in IAAT.[@R35] Further, deterioration of insulin resistance and adiposity may be induced by high DPP4 levels.[@R36] These effects of high DPP4 levels could be particularly detrimental to Asian Indians who already have higher magnitude of subclinical inflammation and abdominal adiposity as compared with other races,[@R37] thus escalating cardiovascular risk.[@R38] Whether high levels of circulating plasma DPP4 levels have any influence on therapy with DPP4 inhibitors remains to be researched. Finally, in view of high load of   diabetes-related complications, the relationship of AGE products and circulating DPP4 levels in Asian Indians needs further research.[@R39]

In summary, non-obese Asian Indian patients with T2DM on metformin have significantly higher circulating plasma DPP4 level as compared with non-obese, non-diabetic controls, which correlate with fasting insulin and LDL-C levels, triceps skinfolds, and intra-abdominal adiposity, and presence of diabetes. However, this is a cross-sectional study and detailed studies on DPP4 expression in intra-abdominal adipocytes need to be conducted to validate our observations.
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